Intensity Therapeutics

Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company focused on developing intratumoral cancer therapies for solid tumors. Its lead product candidate, INT230-6, is designed to be injected directly into tumors to help destroy cancer cells locally while also promoting a broader immune response against cancer throughout the body. The company’s platform centers on proprietary drug-conjugation technology that combines active anti-cancer agents with molecules that improve dispersion within tumors and cellular uptake. Intensity Therapeutics is currently advancing programs in cancers such as soft tissue sarcoma and triple-negative breast cancer, with an emphasis on addressing both localized disease and metastatic spread. Headquartered in Shelton, Connecticut, Intensity Therapeutics operates within the oncology biotechnology segment, where its work contributes to the development of novel immune-based treatment approaches for patients with solid tumor cancers.